Healthcare and Distribution Services - Audon Trap & Partners
Healthcare and Distribution Services - Audon Trap & Partners
Healthcare and Distribution Services - Audon Trap & Partners
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
<strong>Healthcare</strong> <strong>and</strong> <strong>Distribution</strong> <strong>Services</strong><br />
Sudco of Multipharma Flex Pharma Advisor to buyer<br />
Holl<strong>and</strong> Corporate Finance advised Flex Pharma on the acquisition of Sudco, a<br />
producer of OTC products.<br />
Flex Pharma is a producer of pharmaceuticals, vitamin supplements <strong>and</strong> dermocosmetics.<br />
Sudco was part of Multipharma. Multipharma is a subsidiary of Novartis<br />
(www.novartis.com), a pharmaceutical multinational which is engaged in the<br />
research, development, manufacture <strong>and</strong> marketing of medicines.<br />
Symare Pharma Tramedico International Advisor to buyer<br />
/ Flex Pharma<br />
Holl<strong>and</strong> Corporate Finance advised Tramedico International (www.tramedico.nl) <strong>and</strong><br />
the joint venture on the formation of the joint venture Symare Pharma.<br />
Tramedico International focuses on the marketing, sales <strong>and</strong> distribution of<br />
medicines <strong>and</strong> self-care products in the Benelux. Flex Pharma is a producer of<br />
pharmaceuticals, vitamin supplements <strong>and</strong> dermo-cosmetics.<br />
M&A International Inc.<br />
member firm:<br />
SteriGenics International, Inc. Ion Beam Applications s.a. Advisor to seller TM Capital Corp.<br />
SteriGenics International, Inc. (NASDAQ: STER) is a leading provider of contract<br />
irradiation <strong>and</strong> sterilization services for health care <strong>and</strong> other markets.<br />
TM Capital assisted SteriGenics in completing three strategic acquisitions which<br />
brought the company into new geographic markets, new sterilization technologies<br />
<strong>and</strong> new market applications.<br />
TM Capital then assisted SteriGenics in completing its $214 million sale to Ion Beam<br />
Applications s.a. (BB: IBAB), a leading provider of particle accelerators for health<br />
care <strong>and</strong> other markets. TM Capital also provided a fairness opinion in connection<br />
with the sale of SteriGenics to IBA.<br />
Holl<strong>and</strong> Corporate Finance<br />
Holl<strong>and</strong> Corporate Finance<br />
30